Abstract
Amyotrophic Lateral Sclerosis (ALS) is a rapidly progressive neurodegenerative disease with no effective treatment and unclear pathophysiology. The diagnosis is difficult, often being delayed by 10 to 12 months after the onset of symptoms and the clinical presentation is variable, also including cognitive and behavioral changes. Thus, the use of reliable biomarkers for early diagnosis and…